Sanofi
Tracked across 51 events · 674 articles · First seen Dec 05, 2025 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Sanofi announced positive Phase 2 clinical trial results for its drug lunsekimig in respiratory diseases, which could lead to new treatment options and future revenue streams.
Apr 07, 2026 · 6 articles
Business
Impact: Sanofi, in collaboration with Regeneron Pharmaceuticals, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
Business
Impact: Sanofi is extending its commitment to improving lives beyond healthcare through its foundation's strengthened focus on children and young people, which could enhance its corporate social responsibility image.
Jun 25, 2026 · 6 articles
Regulatory
Impact: Sanofi is under formal antitrust investigation by the International — European Commission for allegedly disparaging a rival flu vaccine, which could lead to penalties and reputational damage.
Jun 26, 2026 · 6 articles
Business
Impact: Sanofi has received priority review for its drug venglustat, which could significantly expand its portfolio in lysosomal storage diseases and provide a new revenue stream if approved.
May 28, 2026 · 6 articles
Business
Impact: Sanofi is adopting Snowflake Inc.'s AI Data Cloud and Elementum's AI solutions to accelerate drug development, improve sales operations, and become an AI-powered biopharma company. This move is expected to enhance its operational efficiency and innovation capabilities.
Jun 02, 2026 · 6 articles
Business
Impact: Sanofi launched its 2026 global employee stock purchase plan, Action 2026, to involve employees in the company's growth and results. This initiative aims to strengthen employee commitment and ownership in the company.
Jun 04, 2026 · 8 articles
Business
Impact: Sanofi is the subject of the report, disclosing its half-year financial results and regulatory filings.
Jul 30, 2026 · 13 articles
Business
Impact: Sanofi expands its collaboration with Aqemia by nominating a new therapeutic target, demonstrating continued investment in AI-driven drug discovery, though the financial commitment is small relative to its overall R&D budget.
Jul 17, 2026 · 6 articles
Business
Impact: Sanofi is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Domestic
Impact: Sanofi is a major insulin maker that has moved to cut the cost of insulin and offers a savings program for people without health insurance.
Apr 02, 2026 · 6 articles
Business
Impact: Sanofi participated in a concurrent private placement, purchasing 500,000 shares for $7.5 million, and has a prior $1.5 billion research collaboration with Scribe. This deepens Sanofi's strategic involvement in gene editing and cardiovascular therapies.
Jul 06, 2026 · 25 articles
Business
SK Biopharmaceuticals, a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting on August 19, 2026. The brand name stands for Science, Breakthroughs…
Impact: Sanofi is a key partner, having licensed rovadicitinib from Sino Biopharmaceutical in a deal valued up to US$1.53 billion. This adds a promising asset to Sanofi's pipeline, potentially enhancing its respiratory and immunology portfolio.
Jul 20, 2026 · 6 articles
Regulatory
Impact: Sanofi is co-developing the GBP410 pneumococcal vaccine candidate with Altor BioScience. The financing secured by Altor BioScience will indirectly support the joint development efforts.
May 29, 2026 · 6 articles
Business
Impact: Sanofi's Lantus faces new competition from Awiqli, which offers less frequent dosing and lower cost per unit.
Jul 09, 2026 · 21 articles
Business
Impact: Sanofi participated in the symposium, reflecting its interest in sustainable manufacturing technologies.
Jul 20, 2026 · 6 articles
Tech
Impact: Major contributing member; contributes data and expertise.
Jul 13, 2026 · 6 articles
Regulatory
On August 5, 2026, the U.S. United States — Food and Drug Administration (FDA) approved Moderna's mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine, for adults aged 50 and older. The approval covers traditional approval…
Impact: Sanofi's high-dose flu vaccine served as a comparator in trials; the new mRNA vaccine may compete with its products.
Aug 05, 2026 · 105 articles
Domestic
Impact: Sanofi, a hepatitis B vaccine maker, defended its products as safe, and its U.S.-listed shares ended up 1.3%.
Dec 05, 2025 · 7 articles
Tech
Impact: Sanofi is an early adopter of YesWeHack's Agentic Pentest, suggesting a proactive approach to enhancing their cybersecurity defenses.
Jun 25, 2026 · 6 articles
Regulatory
Impact: Co-marketer of Praluent; faces similar competitive pressure.
Jul 16, 2026 · 93 articles
Tech
Impact: Sanofi's head of exploratory biomarkers, Zhang Rui, provided a positive testimonial about the panel's utility in drug development, indicating potential collaboration or adoption.
Jul 28, 2026 · 6 articles
Business
Aimwell Partners (OTC:AIMN), operating as AimwellBio, announced on August 13, 2026, the availability of a comprehensive investor briefing covering its recently acquired Trustr intellectual property portfolio. The portfolio includes a U.S. patent family for behavioral…
Impact: Sanofi piloted the technology in a program for moderate-to-severe asthma, demonstrating real-world application. This event does not affect Sanofi directly.
Aug 13, 2026 · 6 articles
Business
Aimwell Bio, a healthcare intelligence platform company, announced the executed assignment of the Trustr intellectual property portfolio, a patented behavioral engagement system designed to measure real-world patient behavior and use data-driven interventions to support medication…
Impact: Sanofi conducted a pilot with the Trustr technology in moderate-to-severe asthma, validating its potential. This event does not directly affect Sanofi's operations or financials.
Aug 17, 2026 · 6 articles
Regulatory
Pulse Pharmaceuticals, a Hyderabad-based nano pharmaceutical drug delivery company, received approval from the India — Drugs Controller General of India (DCGI) for its nano-carrier entrapped Vitamin D3 oral dispersion. The approval, announced on August 20,…
Impact: Already a customer of Pulse's manufacturing, the approval may strengthen their supply relationship.
Aug 20, 2026 · 6 articles
Tech
Impact: Sanofi is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Impact: Sanofi is a partner of Orano in developing targeted alpha therapies, indicating potential future collaboration and market opportunities in cancer treatment.
Jul 01, 2026 · 9 articles
Business
Impact: Sanofi is mentioned as a customer of Cursor in the EMEA region, indicating its adoption of Cursor's AI coding platform.
Jun 09, 2026 · 8 articles
Regulatory
Impact: Sanofi is one of the companies whose drug approvals are being bet on, but is not directly involved.
Jul 16, 2026 · 7 articles
Tech
Impact: Sanofi collaborates with Nurix on a STAT6 degrader, but this event does not directly affect that program.
Aug 04, 2026 · 6 articles
+ 21 more events
View on Dashboard
90
SK Biopharmaceuticals licensed rovadicitinib to Sanofi SanofiSino Biopharmaceutical...
ERGEN INTELLIGENCE
Track Sanofi live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard